Shares of Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) are en feugo today as FDA approval for Krystexxa has now led to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE